In 2010, a European study first reported that a combination of autoantibodies against six TAAs, including p53, CAGE, NY-ESO-1, Annexin 1, GBU4-5, and SOX2, had a sensitivity of 36%–39% and a specificity of nearly 90% in lung cancer diagnosis [9]. Here, SOX2 is linked to lung carcinoma.